Kiralda (Gadobutrol)

Gadobutrol is a paramagnetic chelate that shortens the T1 relaxation time of nearby water protons. When injected, it distributes into the extracellular fluid and alters local magnetic fields, producing a higher signal on T1‑weighted MRI sequences, which makes tissues appear brighter and improves contrast between normal and abnormal areas.

The dose of Kiralda is determined by the prescribing physician based on the specific MRI protocol, patient weight, and clinical indication. Dosing is individualized and should follow the recommendations in the product labeling and the radiologist’s instructions.

Safety data for gadobutrol in pregnancy and lactation are limited. It should only be used when clearly needed and when the potential diagnostic benefit outweighs any possible risk to the fetus. Breastfeeding mothers should discuss use with their healthcare provider, as the drug may be excreted in milk.

To order Kiralda, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

Gadobutrol (Kiralda) is a high‑relaxivity, non‑ionic gadolinium chelate that provides strong T1 shortening at a relatively low dose compared with some older agents. Its safety profile is comparable to other macrocyclic gadolinium agents, with a lower risk of dissociation and nephrogenic systemic fibrosis, especially in patients with normal renal function.

Kiralda should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from direct sunlight, moisture and extreme temperatures. Do not freeze the solution, and inspect the vial for particulate matter before use.

Kiralda is administered as an intravenous injection, typically as a bolus or a slow infusion immediately before the MRI examination. The exact rate and volume are determined by the imaging protocol and the prescribing clinician.

The most serious risks include severe allergic reactions such as anaphylaxis, and nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment. Prompt recognition of these reactions and appropriate medical intervention are essential.

Kiralda should be avoided in patients with known hypersensitivity to gadobutrol or any component of the formulation, and in those with severe renal impairment (eGFR < 30 mL/min/1.73 m²) due to the risk of NSF. Caution is also advised in pregnant or breastfeeding women unless the benefit justifies the potential risk.